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AMP-activated protein kinase (AMPK) is a keymetabolic regulator. Recent work (Chen et al., 2009) elucidates
the structural interaction between the autoinhibitory sequence and the kinase domain of the AMPK catalytic
subunit. Enhanced understanding of the molecular mechanics of AMPK activation might lead to novel
therapeutic approaches.AMP-activated protein kinase (AMPK) has
emerged as an important regulator of di-
verse metabolic pathways, mitochondrial
biogenesis, cell polarity, and cell growth.
Highly regulated by the cellular energetic
state, AMPK activity is increased by AMP
and antagonized by ATP. When energy
demand outstrips ATP production, net
ATP breakdown ensues, increasing intra-
cellular AMP concentration and activating
AMPK. Thus, AMPK functions as a cellular
fuel gauge that detects energetic stress,
such as occurs during ischemia, hypoxia,
and hypoglycemia, or during exercise in
skeletal muscle and heart (Young, 2008).
AMPK also receives cues from the extra-
cellular environment and is activated by
hormones (adiponectin and leptin) and
cytokines (IL-6 and MIF) (Miller et al.,
2008). Beyond its internal cell-centric func-
tion, AMPK in the hypothalamus modu-
lates signals that regulate whole-body
energy homeostasis.
Once activated, AMPK stimulates en-
ergy-generating catabolic pathways and
inhibits energy-requiring anabolic pro-
cesses. Contemporary interest in AMPK
was launched by observations that acti-
vated AMPK accelerates glucose trans-
port, glycolysis, and fatty acid oxidation,
while also inhibiting protein and glycogen
synthesis. Because AMPK also interacts
with intracellular signaling pathways and
modulates gene expression, it has abroad
range of physiologic actions in most cells.
Research on AMPK structure has the
potential to elucidate the specific mecha-
nisms regulating the kinase and could
lead to novel therapeutic strategies for
AMPK activation. However, understand-
ing the molecular structure of the intact
AMPK molecule has proved challenging,
because AMPK is a heterotrimeric com-
plex of a, b, and g subunits. The a subunitcontains the kinase domain and an adja-
cent autoinhibitory sequence, the b sub-
unit includes a glycogen binding domain
and bridges the a and g subunits, and
the g subunit contains nucleotide-binding
(Bateman) domains that are essential for
AMPK activation by AMP (Figure 1).
AMPK a subunit activity is critically de-
pendent on the phosphorylation of Thr172
within its activation loop. Thr172 is phos-
phorylated by upstream LKB1 and Ca2+/
calmodulin-dependent protein kinase
kinase (CaMKK), and dephosphorylated
by protein phosphatases (PP2C). AMP
binding to the g subunit has the dual effect
of inducing allosteric activation and inhib-
iting Thr172 dephosphorylation (Davies
et al., 1995). This latter effect is critical in
the regulation of AMPK activity.
Previous crystal structures have pro-
vided insight into the configuration of
AMPK’s critical functional domains (Scott
et al., 2009). The AMPK equivalent kinase
in yeast (SNF1) has been highly utilized as
a model system for structural analysis.
The SNF1 complex includes the proteins
Snf1, Sip2, and Snf4, orthologs of the
AMPK a, b, and g subunits, respectively.
Core fragments of the heterotrimeric
SNF1 complex have also been crystal-
lized (Amodeo et al., 2007). However, one
important caveat to these structures is
that the yeast SNF1 complex is not actu-
ally activated by AMP, the cardinal feature
of mammalian AMPK.
The holy grail of AMPK structural bio-
logy, crystallization of the intact mamma-
lian heterotrimeric AMPK complex, has
proved elusive. However, the full-length
mammalian AMPK g subunit and frag-
ments of the b and g subunits have
recently been crystallized, with analysis
yielding a core structure (Xiao et al., 2007).
This revealed the unanticipated discoveryCell Metabthat g subunits contain three AMP binding
sites, one of which is nonexchangeable,
challenging the existing paradigm of only
2 AMP binding sites. Thus, despite a
substantial amount of recent research on
the structure and function of AMPK, the
‘‘molecular gymnastics’’ that actually
transduce AMPK catalytic activation
remain a puzzle.
In a recent issue of Nature, Chen et al.
take someof themystery out of this puzzle
(Chen et al., 2009). They have success-
fully crystallized a fragment of S. pombe
Snf1, containing both the kinase and
autoinhibitory domains. Their novel crystal
structure indicates that the Snf1 auto-
inhibitory sequence interacts with the
‘‘backside’’ of the bilobar kinase domain,
constraining it in an open and inactive
configuration (Figure 1). They have also
crystallized a novel S. cerevisiae Snf1
kinase domain fragment that is phosphor-
ylated in the activation loop. Lacking the
autoinhibitory domain, this structure has
a more closed configuration with higher
activity than previously identified non-
phosphorylated kinase domain fragments
from S. pombe. Taken together, these
data suggest that the autoinhibitory do-
main might exert a molecular ‘‘Heimlich
maneuver’’ on the kinase domain, forcing
it open from the backside and preventing
it from closing into its active configuration.
Based on their initial findings, Chen
et al. identified candidate amino acids
that mediate the interaction between the
autoinhibitory sequence and the kinase
domain (Chen et al., 2009). Point muta-
tions of these amino acids increased the
catalytic activity of both the S. pombe
Snf1 fragment and rat AMPK a1 subunits.
Notably, these same interface mutations
increased the activity of the intact rat
AMPK abg complex, independent of theolism 10, July 8, 2009 ª2009 Elsevier Inc. 5
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slowed dephosphorylation of a subunit
Thr172 by PP2Ca and effectively abol-
ished the AMP dependence of this de-
phosphorylation. Because the phosphor-
ylation state of the Thr172 site is such
a critical determinant of AMPK activity,
these latter findings hold perhaps the
greatest physiologic significance. They
specifically indicate that the autoinhibi-
tory sequence has an important role in
modulating Thr172 phosphorylation.
These observations build on a legacy
of prior investigations into the molecular
regulation of AMPK, including recent
studies that suggested a backside inter-
action between the autoinhibitory and
kinase domains (Pang et al., 2007; Riek
et al., 2008). The model proposed by
Chen et al. sandwiches the autoinhibitory
sequence between the a subunit kinase
domain and the g subunit, potentially
enabling it to transduce AMP binding
into activation of the kinase domain (Fig-
ure 1). Their results also argue that the
autoinhibitory sequence of the kinase
domain does not function as a pseudo-
substrate. This contrasts with other well-
known protein kinases, such as protein
kinase C, that are inhibited by pseudo-
substrate domains.
While the findings of Chen et al. en-
hance our understanding of the molec-
ular mechanics of AMPK regulation, key
questions remain.Most importantmecha-
nistically, how does AMP binding actually
alter the interaction between the autoinhi-
bitory and kinase domains? In particular,
how does AMP binding to the g subunit
block dephosphoryation of the a subunit
Thr172, whose phosphorylation state is
so critical to the activity of AMPK? In terms
of translating these findings, can the auto-
inhibitory domain be targeted as a novel
Figure 1. AMPK Activation Model
The AMPK complex is comprised of three subunits: the a catalytic subunit (blue) including the bilobar
kinase domain (KD) that contains Thr172 in the activation loop of the catalytic cleft and an autoinhibitory
domain (AID) (light blue) sandwiched between the backside of the kinase domain and the g subunit; the
b subunit (dark green) containing a glycogen binding domain (GBD) and binding sites for both the a and
g subunits; the g subunit, which contains the nucleotide binding sites (Bateman domains). When the
AMP/ATP ratio is low, little AMP is bound and AMPK is in its inactive form, with the autoinhibitory AID teth-
ering the backside of the kinase domain in its inactive open configuration. This open cleft allows both
upstream kinases (LKB1 and CaMKK) and protein phosphatases (PP2C) to interact with Thr172, maintain-
ing low phosphorylation of this critical activating site. When the AMP/ATP ratio increases with energetic
stress, more AMP is bound to the g subunit and the autoinhibitory subunit releases from the hinge of
the kinase domain, which then assumes its active more closed configuration. The closed cleft also inhibits
access of protein phosphatase to Thr 172, favoring the action of the upstream kinases to maintain a high
phosphorylation state of the activating site. Adapted from Pang et al., 2007; Xiao et al., 2007; Riek et al.,
2008; Chen et al., 2009.6 Cell Metabolism 10, July 8, 2009 ª2009 Elsevier Inc.strategy for activating AMPK? Prior phar-
macologic agents have activated AMPK
indirectly through increasing AMP con-
centration (metformin), serving as AMP
mimetics (AICAR), or through binding to
the b subunit (A769662). Recent results
already provide an initial answer to this
question with proof-of-principle findings
that small molecules targeted at the auto-
inhibitory domain might activate AMPK
(Pang et al., 2008).
Thus, the authors are to be congratu-
lated on their contribution, which helps
to unravel the molecular twists and turns
that mediate AMPK activation. Further
investigation in this field hopefully will
advance the treatment of conditions in
which AMPK is likely to have an important
role, including diabetes, cancer, and heart
disease.
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